LUND, Sweden, Aug. 11, 2022 /PRNewswire/ -- The California
Department of Public Health has granted Immunovia, Inc., the
American subsidiary of Immunovia AB (Nasdaq :IMMNOV) (Stockholm: IMMNOV), a Clinical and Public
Health Laboratory license, allowing physicians in California to order the IMMray PanCan-d test
for their patients.
"People at risk for pancreatic cancer need better tools for
early detection. We are thrilled that this approval enables us to
make IMMray PanCan-d available to clinicians in California who care for those at risk." says
Jeff Borcherding, Chief Executive
Officer of Immunovia, Inc.
For more information, please contact:
CEO and President
Karin Almqvist Liwendahl
Chief Financial Officer
The information was submitted for publication on August 10, 2022, at 09:55
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download: